Wang, Rou-HsinRou-HsinWangCHIEN-JEN CHANGChen, Chien-HungChien-HungChenLiu, Kuang-KaiKuang-KaiLiuChao, Jui-IJui-IChao2024-02-262024-02-26202318715206https://scholars.lib.ntu.edu.tw/handle/123456789/639940Lung cancer has become one of the leading causes of cancer incidence and mortality worldwide. Non-small cell lung carcinoma (NSCLC) is the most common type among all lung cancer cases. NSCLC patients contained high levels of activating epidermal growth factor receptor (EGFR) mutations, such as exon 19 deletion, L858R and T790M. Osimertinib, a third-generation of EGFR tyrosine kinase inhibitor (EGFR-TKI), has therapeutic efficacy on the EGFR-T790M mutation of NSCLC patients; however, treatment of osimertinib still can induce drug resistance in lung cancer patients. Therefore, investigation of the drug resistance mechanisms of osimertinib will provide novel strategies for lung cancer therapy.enEGFR; N-cadherin; PD-L1; cell migration; drug resistance; osimertinib[SDGs]SDG3journal article10.2174/1871520623666230223111217368156582-s2.0-85160910134https://api.elsevier.com/content/abstract/scopus_id/85160910134